148 related articles for article (PubMed ID: 27146400)
1. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
Ouerdani A; Goutagny S; Kalamarides M; Trocóniz IF; Ribba B
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1263-73. PubMed ID: 27146400
[TBL] [Abstract][Full Text] [Related]
2. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
3. Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis.
Li KL; Djoukhadar I; Zhu X; Zhao S; Lloyd S; McCabe M; McBain C; Evans DG; Jackson A
Neuro Oncol; 2016 Feb; 18(2):275-82. PubMed ID: 26311690
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab Therapy of Neurofibromatosis Type 2 Associated Vestibular Schwannoma in Japanese Patients.
Fujii M; Ichikawa M; Iwatate K; Bakhit M; Yamada M; Kuromi Y; Sato T; Sakuma J; Saito K
Neurol Med Chir (Tokyo); 2020 Feb; 60(2):75-82. PubMed ID: 31902875
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
Karajannis MA; Legault G; Hagiwara M; Giancotti FG; Filatov A; Derman A; Hochman T; Goldberg JD; Vega E; Wisoff JH; Golfinos JG; Merkelson A; Roland JT; Allen JC
Neuro Oncol; 2014 Jan; 16(2):292-7. PubMed ID: 24311643
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
Goutagny S; Raymond E; Esposito-Farese M; Trunet S; Mawrin C; Bernardeschi D; Larroque B; Sterkers O; Giovannini M; Kalamarides M
J Neurooncol; 2015 Apr; 122(2):313-20. PubMed ID: 25567352
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Blakeley JO; Ye X; Duda DG; Halpin CF; Bergner AL; Muzikansky A; Merker VL; Gerstner ER; Fayad LM; Ahlawat S; Jacobs MA; Jain RK; Zalewski C; Dombi E; Widemann BC; Plotkin SR
J Clin Oncol; 2016 May; 34(14):1669-75. PubMed ID: 26976425
[TBL] [Abstract][Full Text] [Related]
8. A 4-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas.
Goutagny S; Giovannini M; Kalamarides M
J Neurooncol; 2017 Jun; 133(2):443-445. PubMed ID: 28434114
[No Abstract] [Full Text] [Related]
9. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Plotkin SR; Merker VL; Halpin C; Jennings D; McKenna MJ; Harris GJ; Barker FG
Otol Neurotol; 2012 Aug; 33(6):1046-52. PubMed ID: 22805104
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.
Hochart A; Gaillard V; Baroncini M; André N; Vannier JP; Vinchon M; Dubrulle F; Lejeune JP; Vincent C; Nève V; Sudour Bonnange H; Bonne NX; Leblond P
J Neurooncol; 2015 Sep; 124(2):229-36. PubMed ID: 26022982
[TBL] [Abstract][Full Text] [Related]
11. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Plotkin SR; Duda DG; Muzikansky A; Allen J; Blakeley J; Rosser T; Campian JL; Clapp DW; Fisher MJ; Tonsgard J; Ullrich N; Thomas C; Cutter G; Korf B; Packer R; Karajannis MA
J Clin Oncol; 2019 Dec; 37(35):3446-3454. PubMed ID: 31626572
[TBL] [Abstract][Full Text] [Related]
13. Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
Farschtschi S; Kollmann P; Dalchow C; Stein A; Mautner VF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3857-60. PubMed ID: 25794543
[TBL] [Abstract][Full Text] [Related]
14. Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports.
Goutagny S; Kalamarides M
Neurochirurgie; 2018 Nov; 64(5):370-374. PubMed ID: 28162254
[TBL] [Abstract][Full Text] [Related]
15. Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality.
Gugel I; Zipfel J; Hartjen P; Kluwe L; Tatagiba M; Mautner VF; Schuhmann MU
Childs Nerv Syst; 2020 Oct; 36(10):2471-2480. PubMed ID: 32548671
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
Eminowicz GK; Raman R; Conibear J; Plowman PN
J Laryngol Otol; 2012 Jan; 126(1):79-82. PubMed ID: 22004800
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes.
Lu VM; Ravindran K; Graffeo CS; Perry A; Van Gompel JJ; Daniels DJ; Link MJ
J Neurooncol; 2019 Sep; 144(2):239-248. PubMed ID: 31254266
[TBL] [Abstract][Full Text] [Related]
19. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma.
Fujii M; Kobayakawa M; Saito K; Inano A; Morita A; Hasegawa M; Mukasa A; Mitsuhara T; Goto T; Yamaguchi S; Tamiya T; Nakatomi H; Oya S; Takahashi F; Sato T; Bakhit M; On Behalf Of The BeatNF Trial Investigators
Curr Oncol; 2021 Jan; 28(1):726-739. PubMed ID: 33572546
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
Farschtschi S; Merker VL; Wolf D; Schuhmann M; Blakeley J; Plotkin SR; Hagel C; Mautner VF
Acta Neurol Scand; 2016 Jun; 133(6):475-80. PubMed ID: 26369495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
